TCIM
GALT icon

TIAA CREF Investment Management’s Galectin Therapeutics GALT Stock Holding History

TIAA CREF Investment Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20,798
Closed -$57K – 3116
2015
Q2 		$57K Sell
20,798
-41,239
-66% -$124K ﹤0.01% 3191
2015
Q1 		$208K Hold
62,037
– – ﹤0.01% 3058
2014
Q4 		$215K Sell
62,037
-2,547
-4% -$11.3K ﹤0.01% 3092
2014
Q3 		$325K Sell
64,584
-1,611
-2% -$12.5K ﹤0.01% 3051
2014
Q2 		$914K Buy
+66,195
New +$824K ﹤0.01% 2766

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TIAA CREF Investment Management's GALT Position: Q3 2015 in Review

TIAA CREF Investment Management sold out of Galectin Therapeutics (GALT) in Q3 2015, closing a stake of 20,798 shares — an estimated $57K sold.

TIAA CREF Investment Management first reported a position in GALT in Q2 2014 and held it in 5 quarters. The position peaked at $914K in Q2 2014. 51 funds tracked by Wall St. Rank hold GALT as of Q3 2015.

  • TIAA CREF Investment Management reported no remaining Galectin Therapeutics position as of Q3 2015 after selling out during the quarter.
  • TIAA CREF Investment Management sold 20,798 Galectin Therapeutics shares in Q3 2015, an estimated $57K.
  • TIAA CREF Investment Management first reported a position in Galectin Therapeutics in Q2 2014 and held it in 5 quarters.
  • TIAA CREF Investment Management's Galectin Therapeutics position peaked at $914K in Q2 2014.
  • 51 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2015.

Based on TIAA CREF Investment Management's 13F filing for Q3 2015, filed 13 Nov 2015.